PT1159298E - Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv - Google Patents

Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv Download PDF

Info

Publication number
PT1159298E
PT1159298E PT00911492T PT00911492T PT1159298E PT 1159298 E PT1159298 E PT 1159298E PT 00911492 T PT00911492 T PT 00911492T PT 00911492 T PT00911492 T PT 00911492T PT 1159298 E PT1159298 E PT 1159298E
Authority
PT
Portugal
Prior art keywords
hiv
antigens
peptides
vaccine compositions
hiv peptides
Prior art date
Application number
PT00911492T
Other languages
English (en)
Inventor
Birger Soerensen
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Publication of PT1159298E publication Critical patent/PT1159298E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
PT00911492T 1999-03-04 2000-03-02 Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv PT1159298E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19991078A NO311807B1 (no) 1999-03-04 1999-03-04 HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Publications (1)

Publication Number Publication Date
PT1159298E true PT1159298E (pt) 2008-09-04

Family

ID=19903050

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00911492T PT1159298E (pt) 1999-03-04 2000-03-02 Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv

Country Status (23)

Country Link
US (4) US6706859B1 (pt)
EP (1) EP1159298B1 (pt)
JP (5) JP2002541069A (pt)
CN (4) CN101328209A (pt)
AT (1) ATE397014T1 (pt)
AU (1) AU771827B2 (pt)
BR (1) BR0008741A (pt)
CA (1) CA2363947C (pt)
CY (1) CY1108299T1 (pt)
CZ (1) CZ300505B6 (pt)
DE (1) DE60039036D1 (pt)
DK (1) DK1159298T3 (pt)
EA (1) EA004802B9 (pt)
ES (1) ES2307496T4 (pt)
HK (1) HK1044778B (pt)
HU (1) HU229282B1 (pt)
ID (1) ID30497A (pt)
NO (1) NO311807B1 (pt)
NZ (4) NZ514619A (pt)
PT (1) PT1159298E (pt)
SK (1) SK287382B6 (pt)
WO (1) WO2000052040A1 (pt)
ZA (1) ZA200107072B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398816A1 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
DK2392587T3 (en) 2006-03-10 2016-05-23 Peptcell Ltd Peptide sequences and compositions
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
EP2646459B1 (en) * 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTICS
JP2015520179A (ja) * 2012-06-06 2015-07-16 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ワクチン
JP6310909B2 (ja) * 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3033106A1 (en) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunoadjuvant compositions and uses thereof
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015086738A2 (en) * 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine
WO2015110666A1 (en) 2014-01-27 2015-07-30 Bionor Immuno As Method for the vaccination against hiv
US10449245B2 (en) 2014-01-27 2019-10-22 Bionor Immuno As Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
WO2015110659A1 (en) * 2014-01-27 2015-07-30 Bionor Immuno As Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
WO2015154031A1 (en) 2014-04-03 2015-10-08 Amgen Inc. Method for preparing amg 416
EP3166633A1 (en) 2014-07-11 2017-05-17 Bionor Immuno AS Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230222A1 (en) 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression of HTLV-III gag-Gene
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
NZ226026A (en) 1987-09-04 1991-03-26 Wellcome Found Immunoassay for an antibody using recombinant antigens expressed in two different genera
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
EP0356007A3 (en) 1988-07-22 1991-07-03 Medical Research Council Antigenic determinants
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
FR2703252B1 (fr) * 1993-03-31 1996-09-06 Fernand Narbey Torossian Complexe immunomodulateur anti SIDA.
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
AU6727798A (en) * 1997-03-10 1998-09-29 Roche Diagnostics Gmbh Method for simultaneous detection of hiv antigens and hiv antibodies

Also Published As

Publication number Publication date
EP1159298A1 (en) 2001-12-05
BR0008741A (pt) 2002-01-08
SK12402001A3 (sk) 2002-02-05
NZ525751A (en) 2004-10-29
US7709003B2 (en) 2010-05-04
HK1044778A1 (en) 2002-11-01
ES2307496T4 (es) 2015-03-06
JP5695010B2 (ja) 2015-04-01
CA2363947C (en) 2008-05-20
CZ20013195A3 (cs) 2002-02-13
EP1159298B1 (en) 2008-05-28
HUP0200265A2 (en) 2002-06-29
CZ300505B6 (cs) 2009-06-03
US20080107670A1 (en) 2008-05-08
DE60039036D1 (de) 2008-07-10
CN101328210A (zh) 2008-12-24
AU771827B2 (en) 2004-04-01
CY1108299T1 (el) 2014-02-12
WO2000052040A1 (en) 2000-09-08
JP2002541069A (ja) 2002-12-03
CN100387617C (zh) 2008-05-14
CN1346367A (zh) 2002-04-24
CN101328208A (zh) 2008-12-24
JP5814331B2 (ja) 2015-11-17
NZ514619A (en) 2003-10-31
US7311915B2 (en) 2007-12-25
JP5695012B2 (ja) 2015-04-01
US20040259797A1 (en) 2004-12-23
JP2013032384A (ja) 2013-02-14
HU229282B1 (en) 2013-10-28
NZ525753A (en) 2004-10-29
CA2363947A1 (en) 2000-09-08
JP2014043468A (ja) 2014-03-13
EA200100943A1 (ru) 2002-02-28
CN101328209A (zh) 2008-12-24
EA004802B9 (ru) 2015-03-31
NO991078L (no) 2000-09-05
JP2011074081A (ja) 2011-04-14
DK1159298T3 (da) 2008-08-25
NO991078D0 (no) 1999-03-04
JP2013032386A (ja) 2013-02-14
US7709004B2 (en) 2010-05-04
NO311807B1 (no) 2002-01-28
JP5313998B2 (ja) 2013-10-09
EA004802B1 (ru) 2004-08-26
ZA200107072B (en) 2002-11-27
SK287382B6 (sk) 2010-08-09
ID30497A (id) 2001-12-13
HK1044778B (zh) 2009-04-24
NZ525752A (en) 2004-10-29
AU3335800A (en) 2000-09-21
ES2307496T3 (es) 2008-12-01
US6706859B1 (en) 2004-03-16
ATE397014T1 (de) 2008-06-15
US20080107669A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
MXPA02007413A (es) Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
EP0651818A4 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF IN CONNECTION WITH THE BINDING OF THE CD4 MOLECULE RECEPTOR.
EP1450857A4 (en) NEUTRALIZATION ANTIBODIES WITH SUBSTANTIALLY CROSSED HIV VIRUS ACTIVITY SELECTED USING ENV-CD4 CO-RECEPTOR COMPLEXES
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
EP0397129A3 (en) Process for preparing an improved western blot immunoassay
WO1991009872A3 (en) Hiv-1 env fragment fusion protein
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
EP1016671A3 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
Wahren et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160
Lizeng et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
Warren et al. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
WIELAND et al. Antigenic domains of the HIV-1 vif protein as recognized by human sera and murine monoclonal antibodies
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
McNicholl et al. Immunologic escape as a mechanism of viral persistence in HIV-1 infection
ATE122236T1 (de) Vorläufer des hüllenglykoproteins des hiv-2 retrovirus und verwandte antigene.
TH62264A (th) Hiv เพพไทด์, แอนติเจน องค์ประกอบวัคซีน, ชุดสำเร็จรูปอิมมูโนแอสเสย์ และวิธีสำหรับตรวจหาแอนติบอดีที่ชักนำโดย hiv